LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global pruritus therapeutic market is expected to grow at a CAGR of almost 5% during the forecast period.
This research report titled ‘Global Pruritus Therapeutic Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.
The global pruritus therapeutic market is expected to benefit from the growing focus on new therapy areas such as systemic drugs. Considering pruritus is associated with multiple chronic and acute medical conditions, the prevalence of the disorder remains high globally. For instance, as per the Centers for Disease Control and Prevention (CDC), in the US, around 32 million people have eczema, and approximately 17-18 million have moderate-to-severe eczema. Although pruritus can get triggered from multiple indications, the prevalence of pruritus is the highest amongst eczema patients. Therefore, vendors are aggressively focusing on pipeline development for pruritus therapeutic market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Technavio’s healthcare and life sciences research analysts categorize the global pruritus therapeutic market into the following segments by disease type. They are:
- Renal pruritus
- Cholestatic pruritus
- Hematologic pruritus
- Endocrine pruritus
- Oncological pruritus
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three revenue-generating disease type segments of the global pruritus therapeutic market are discussed below:
Renal pruritus
Renal pruritus is observed in individuals with chronic renal failure and is predominantly seen in individuals receiving hemodialysis. Renal pruritus is also known as uremic pruritus, but it is not due to increased serum urea levels. However, the actual pruritogenic substance is yet to be identified. Pruritus is relatively absent in individuals with acute renal failure, and therefore, the serum mediators other than urea and creatinine are under focus.
According to Srinivas Sashidhar, a lead infectious and rare disease research analyst from Technavio, “In 2013, the National Institutes of Health estimated that around 23 million Americans have chronic kidney failure. The majority of these individuals undergo hemodialysis due to higher acceptance and lack of organ transplant treatment availability. Such instances increase the patient pool of pruritus as generally 41%-43% of patients undergoing hemodialysis are expected to experience pruritic conditions. Thus, the growing incidence of chronic kidney failure will continue leading to a higher patient pool of pruritus, thereby, driving the market growth.”
Cholestatic pruritus
Cholestasis is the condition in which there is decrease or arrest in the flow of bile from the liver to the duodenum, which is associated with acute itching or pruritus. Pruritus is more common with intrahepatic cholestasis than extrahepatic cholestasis. Various theories to understand the pathogenesis of cholestatic pruritus has been elucidated.
“The cholestatic pruritus is also increasing in pediatric patients in recent years, which is leading many vendors to focus on the pediatric cholestatic area of research. For instance, Albireo has a Phase II molecule for pediatric cholestasis. All these factors are expected to contribute to the overall growth of this segment,” adds Srinivas.
Hematologic pruritus
Iron deficiency (with or without anemia) is often regarded as the major cause of hematologic pruritus. Also, glossitis and angular cheilitis are some of the other symptoms of iron deficiency. Iron plays a crucial role in many enzyme activities. Any alterations or disturbance in iron level will impact on the enzymes, and thus its function is impaired. This may lead to the metabolic disturbances and itching.
The growing prevalence of various diseases will contribute to overall market of hematologic pruritus. For instance, iron deficiency is one of the leading blood-related disorders. Similarly, as per the CDC, almost 10% of the US population is facing the problems of anemia. Iron deficiency disorders are disrupting the metabolic pathways of various enzymes, which lead to pruritus with altered body functioning due to enzyme malfunctioning.
The top vendors highlighted by Technavio’s research analysts in this report are:
- Allergan
- GlaxoSmithKline
- Pfizer
- Sanofi
Browse Related Reports:
- Global Veterinary Clostridium Vaccine Market 2017-2021
- Global Retinal Drugs Market 2017-2021
- Global Bone Marrow Transplant Market 2017-2021
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
